Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record.

AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials

Berg, Daniela, Godau, Jana, Trenkwalder, Claudia, Eggert, Karla, Csoti, IIona, Storch, Alexander, Huber, Heiko, Morelli‐Canelo, Monica, Stamelou, Maria, Ries, Vincent, Wolz, Martin, Schneider, Christine, Di Paolo, Thérèse, Gasparini, Fabrizio, Hariry, Sam, Vandemeulebroecke, Marc, Abi‐Saab, Walid, Cooke, Katy, Johns, Donald, Gomez‐Mancilla, Baltazar·2011·Movement Disorders

Abstract

Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa‐induced dyskinesia. Two randomized, double‐blind, placebo‐controlled, parallel‐group, in‐patient studies for Parkinson's disease patients with moderate to severe levodopa‐induced dyskinesia (study 1) and severe levodopa‐induced dyskinesia (study 2) on stable dopaminergic therapy were performed. Patients received 25–150 mg AFQ056 or placebo twice daily for 16 days (both studies). Study 2 included a 4‐day down‐titration. Primary outcomes were the Lang‐Fahn Activities of Daily Living Dyskinesia Scale (study 1), the modified Abnormal Involuntary Movement Scale (study 2), and the Unified Parkinson's Disease Rating Scale–part III (both studies). Secondary outcomes included the Unified Parkinson's Disease Rating Scale–part IV items 32–33. The primary analysis was change from baseline to day 16 on all outcomes. Treatment differences were assessed. Fifteen patients were randomized to AFQ056 and 16 to placebo in study 1; 14 patients were randomized to each group in study 2. AFQ056‐treated patients showed significant improvements in dyskinesias on day 16 versus placebo (eg, Lang‐Fahn Activities of Daily Living Dyskinesia Scale, P = .021 [study 1]; modified Abnormal Involuntary Movement Scale, P = .032 [study 2]). No significant changes were seen from baseline on day 16 on the Unified Parkinson's Disease Rating Scale‐part III in either study. Adverse events were reported in both studies, including dizziness. Serious adverse events (most commonly worsening of dyskinesias, apparently associated with stopping treatment) were reported by 4 AFQ056‐treated patients in study 1, and 3 patients (2 AFQ056‐treated patient and 1 in the placebo group) in study 2. AFQ056 showed a clinically relevant and significant antidyskinetic effect without changing the antiparkinsonian effects of dopaminergic therapy. © 2011 Movement Disorder Society

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.23616

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 175

Metadata

Authors
Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., Huber, H., Morelli‐Canelo, M., Stamelou, M., Ries, V., Wolz, M., Schneider, C., Di Paolo, T., Gasparini, F., Hariry, S., Vandemeulebroecke, M., Abi‐Saab, W., Cooke, K., Johns, D., & Gomez‐Mancilla, B.
Venue
Movement Disorders
Publisher
Wiley
Published
2011-04-11
Volume
26
Issue
7
Pages
1243-1250
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
OpenAlex
W1900959796
Cited by
175
References
0
FWCI
16.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials. https://app.cochat.ai/papers/10.1002/mds.23616
The paper
Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., Huber, H., Morelli‐Canelo, M., Stamelou, M., Ries, V., Wolz, M., Schneider, C., Di Paolo, T., Gasparini, F., Hariry, S., Vandemeulebroecke, M., Abi‐Saab, W., Cooke, K., Johns, D., & Gomez‐Mancilla, B. (2011). AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials. Movement Disorders. https://doi.org/10.1002/mds.23616

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.